{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:02:30Z","timestamp":1791000150682,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":917,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1093\/annonc\/mdx028","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T08:25:10Z","timestamp":1485764710000},"page":"1057-1063","source":"Crossref","is-referenced-by-count":48,"title":["Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma"],"prefix":"10.1016","volume":"28","author":[{"given":"A.K.","family":"Gopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx028_bb0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/asheducation-2009.1.497","article-title":"Standard therapy of advanced Hodgkin lymphoma","author":"Kuruvilla","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1093\/annonc\/mdx028_bb0015","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","article-title":"How I treat relapsed and refractory Hodgkin lymphoma","volume":"117","author":"Kuruvilla","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjh.12878","article-title":"Guidelines for the first line management of classical Hodgkin lymphoma","volume":"166","author":"Follows","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx028_bb0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bbmt.2011.08.012","article-title":"Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era","volume":"18","author":"Keller","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdx028_bb0030","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx028_bb0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2166","article-title":"Brentuximab vedotin administered to platinum-refractory, transplant-naive Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status","volume":"33","author":"Onishi","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdx028_bb0040","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx028_bb0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx028_bb0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V124.21.290.290","article-title":"PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)","volume":"124","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0055","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.4049\/jimmunol.176.5.2808","article-title":"Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells","volume":"176","author":"Raimondi","year":"2006","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdx028_bb0060","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1182\/blood-2011-11-388918","article-title":"Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells","volume":"119","author":"Tai","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0065","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdx028_bb0070","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0080","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Meadows","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0085","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdx028_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdx028_bb0095","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx028_bb0100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2015-10-671826","article-title":"How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant","volume":"127","author":"Alinari","year":"2016","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0105","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx028_bb0110","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0115","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx028_bb0120","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V126.23.584.584","article-title":"PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment","volume":"126","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx028_bb0125","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdx028_bb0130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/0008-5472.CAN-11-0307","article-title":"Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma+IL-17+ polyfunctional T cells that mediate rejection of murine tumors","volume":"72","author":"Marshall","year":"2012","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx028_bb0135","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/imt.14.35","article-title":"PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma","volume":"6","author":"Oh","year":"2014","journal-title":"Immunotherapy"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/5\/1057\/13942795\/mdx028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:14:55Z","timestamp":1624680895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419320071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0923753419320071"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx028","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727454561.793552722","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}